Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

Similar articles for PubMed (Select 20371675)

1.

Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study.

Rojo F, Gracias E, Villena N, Cruz T, Corominas JM, Corradino I, Cedeño M, Campas C, Osorio M, Iznaga N, Bellosillo B, Rovira A, Marsoni S, Gascon P, Serrano S, Sessa C, Crombet T, Albanell J.

Clin Cancer Res. 2010 Apr 15;16(8):2474-82. doi: 10.1158/1078-0432.CCR-09-3042. Epub 2010 Apr 6.

2.

Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients.

Reddy BK, Lokesh V, Vidyasagar MS, Shenoy K, Babu KG, Shenoy A, Naveen T, Joseph B, Bonanthaya R, Nanjundappa, Bapsy PP, Loknatha, Shetty J, Prasad K, Tanvir Pasha CR.

Oral Oncol. 2014 May;50(5):498-505. doi: 10.1016/j.oraloncology.2013.11.008. Epub 2014 Mar 6.

PMID:
24613543
3.

Nimotuzumab with chemoradiation confers a survival advantage in treatment-naïve head and neck tumors over expressing EGFR.

Basavaraj C, Sierra P, Shivu J, Melarkode R, Montero E, Nair P.

Cancer Biol Ther. 2010 Oct 1;10(7):673-81. Epub 2010 Oct 1.

4.

A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies.

You B, Brade A, Magalhaes JM, Siu LL, Oza A, Lovell S, Wang L, Hedley DW, Nicacio LV, Chen EX.

Invest New Drugs. 2011 Oct;29(5):996-1003. doi: 10.1007/s10637-010-9444-0. Epub 2010 May 8.

PMID:
20454832
5.

Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.

Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Roselló J, Nicholson RI, Mendelsohn J, Baselga J.

Cancer Res. 2001 Sep 1;61(17):6500-10.

6.

Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck.

Rodríguez MO, Rivero TC, del Castillo Bahi R, Muchuli CR, Bilbao MA, Vinageras EN, Alert J, Galainena JJ, Rodríguez E, Gracias E, Mulén B, Wilkinson B, de Armas EL, Pérez K, Pineda I, Frómeta M, Leonard I, Mullens V, Viada C, Luaces P, Torres O, Iznaga N, Crombet T.

Cancer Biol Ther. 2010 Mar 1;9(5):343-9. Epub 2010 Mar 20.

7.

Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib.

Agulnik M, da Cunha Santos G, Hedley D, Nicklee T, Dos Reis PP, Ho J, Pond GR, Chen H, Chen S, Shyr Y, Winquist E, Soulieres D, Chen EX, Squire JA, Marrano P, Kamel-Reid S, Dancey J, Siu LL, Tsao MS.

J Clin Oncol. 2007 Jun 1;25(16):2184-90.

8.

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.

Cancer Res. 2004 Aug 1;64(15):5355-62.

9.

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.

Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE.

J Clin Oncol. 2003 May 15;21(10):1980-7.

PMID:
12743152
10.

A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors.

Okamoto W, Yoshino T, Takahashi T, Okamoto I, Ueda S, Tsuya A, Boku N, Nishio K, Fukuoka M, Yamamoto N, Nakagawa K.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1063-71. doi: 10.1007/s00280-013-2277-8. Epub 2013 Sep 18.

PMID:
24046058
11.

EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.

Jedlinski A, Ansell A, Johansson AC, Roberg K.

J Oral Pathol Med. 2013 Jan;42(1):26-36. doi: 10.1111/j.1600-0714.2012.01177.x. Epub 2012 May 29.

PMID:
22643066
12.

Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma.

Tsien CI, Nyati MK, Ahsan A, Ramanand SG, Chepeha DB, Worden FP, Helman JI, D'Silva N, Bradford CR, Wolf GT, Lawrence TS, Eisbruch A.

Head Neck. 2013 Sep;35(9):1323-30. doi: 10.1002/hed.23128. Epub 2012 Aug 21.

13.

Spatial relationship of phosphorylated epidermal growth factor receptor and activated AKT in head and neck squamous cell carcinoma.

Nijkamp MM, Hoogsteen IJ, Span PN, Takes RP, Lok J, Rijken PF, van der Kogel AJ, Bussink J, Kaanders JH.

Radiother Oncol. 2011 Oct;101(1):165-70. doi: 10.1016/j.radonc.2011.06.022. Epub 2011 Jul 19.

PMID:
21775008
14.

Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer.

Pernas FG, Allen CT, Winters ME, Yan B, Friedman J, Dabir B, Saigal K, Mundinger GS, Xu X, Morris JC, Calvo KR, Van Waes C, Chen Z.

Clin Cancer Res. 2009 Apr 1;15(7):2361-72. doi: 10.1158/1078-0432.CCR-08-1011. Epub 2009 Mar 24.

15.

Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma.

Wheeler S, Siwak DR, Chai R, LaValle C, Seethala RR, Wang L, Cieply K, Sherer C, Joy C, Mills GB, Argiris A, Siegfried JM, Grandis JR, Egloff AM.

Clin Cancer Res. 2012 Apr 15;18(8):2278-89. doi: 10.1158/1078-0432.CCR-11-1593. Epub 2012 Feb 20.

16.

Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin.

Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H, Arvind AS.

MAbs. 2009 Jan-Feb;1(1):41-8. Review.

17.

Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.

Le Tourneau C, Siu LL.

Curr Opin Oncol. 2008 May;20(3):256-63. doi: 10.1097/CCO.0b013e3282f9b575. Review.

PMID:
18391623
18.

Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.

Schneider CP, Heigener D, Schott-von-Römer K, Gütz S, Laack E, Digel W, Guschall WR, Franke A, Bodenstein H, Schmidtgen C, Reck M.

J Thorac Oncol. 2008 Dec;3(12):1446-53. doi: 10.1097/JTO.0b013e31818ddcaa.

PMID:
19057271
19.

Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3.

Zhao L, He LR, Xi M, Cai MY, Shen JX, Li QQ, Liao YJ, Qian D, Feng ZZ, Zeng YX, Xie D, Liu MZ.

J Transl Med. 2012 Dec 11;10:249. doi: 10.1186/1479-5876-10-249.

20.

Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer.

Shin DM, Donato NJ, Perez-Soler R, Shin HJ, Wu JY, Zhang P, Lawhorn K, Khuri FR, Glisson BS, Myers J, Clayman G, Pfister D, Falcey J, Waksal H, Mendelsohn J, Hong WK.

Clin Cancer Res. 2001 May;7(5):1204-13.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk